Drugs / Fluorine F 18 Fluorodopa
Fluorine F 18 Fluorodopa
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT02020720 | Jan 2014 → Oct 2019 | brain neoplasm, malignant glioma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT01165632 | Jul 2010 → Nov 2013 | adult anaplastic ependymoma, adult brainstem glioma, adult glioblastoma, adult oligodendroglioma +9 | Mayo Clinic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03242824 | Sep 2017 → Jun 2020 | glioma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluorine F 18 Fluorodopa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03242824 ↗ |
| Modality | Diagnostic / imaging agent | “fluorine F 18 fluorodopa-labeled PET scan” NCT01165632 ↗ |
| Route | Intravenous | “Given IV” NCT01165632 ↗ |